Emil Lou, MD, PhD, FACP, discusses the rationale for evaluating CISH knockout TILs using CRISPR-Cas9 gene editing in metastatic GI cancers.
Emil Lou, MD, PhD, FACP
Advertisement
Articles by Emil Lou, MD, PhD, FACP
Emil Lou, MD, PhD, FACP, discusses the predictive and prognostic value of tumor stroma proportion for survival outcomes in ovarian cancer.
Advertisement
Latest Updated Articles
Dr Lou on the Predictive and Prognostic Utility of Tumor Stroma Proportion in Ovarian CancerPublished: May 15th 2024 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5